Compare AZTA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZTA | NBTX |
|---|---|---|
| Founded | 1978 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | 2018 |
| Metric | AZTA | NBTX |
|---|---|---|
| Price | $18.60 | $41.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $40.60 | $36.00 |
| AVG Volume (30 Days) | ★ 770.5K | 50.0K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $593,821,000.00 | N/A |
| Revenue This Year | $6.99 | $58.17 |
| Revenue Next Year | $5.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.87 | $3.34 |
| 52 Week High | $41.73 | $41.89 |
| Indicator | AZTA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 66.92 |
| Support Level | N/A | $20.11 |
| Resistance Level | $32.32 | $41.89 |
| Average True Range (ATR) | 1.45 | 1.74 |
| MACD | -0.43 | 0.50 |
| Stochastic Oscillator | 11.89 | 92.03 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.